This company has been acquired
DICE Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
DICE Therapeutics has a total shareholder equity of $519.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $550.7M and $31.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$528.38m |
Equity | US$519.06m |
Total liabilities | US$31.62m |
Total assets | US$550.67m |
Recent financial health updates
We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate
May 14Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation
Sep 11Recent updates
We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate
May 14DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher
Oct 11Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation
Sep 11DICE Therapeutics GAAP EPS of -$0.58
Aug 11DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs
Jul 18Financial Position Analysis
Short Term Liabilities: DICE's short term assets ($532.3M) exceed its short term liabilities ($20.6M).
Long Term Liabilities: DICE's short term assets ($532.3M) exceed its long term liabilities ($11.0M).
Debt to Equity History and Analysis
Debt Level: DICE is debt free.
Reducing Debt: DICE had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DICE has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: DICE has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 46.7% each year.